Translational Drug Development   Report issue

For profit Phase 1 Phase 2
Founded: Scottsdale AZ United States (2003)

Organization Overview

First Clinical Trial
2007
NCT00495144
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Translational Drug Development

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Basal Cell (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Cholangiocarcinoma (Phase 1)

Colorectal Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 1)

Hypoxia (Phase 1)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Liver Neoplasms (Phase 1)

Lymphoma (Phase 1)

Lymphoma, T-Cell (Phase 1)

Lymphoma, T-Cell, Cutaneous (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Stomach Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 14
  • # of Trial APIs: 20